Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis
Novartis
Lyell Immunopharma, Inc.
AVM Biotechnology Inc
BeOne Medicines
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Genmab
Genmab
AvenCell Therapeutics, Inc.
Dizal Pharmaceuticals
Vironexis Biotherapeutics Inc.
Pfizer
Galapagos NV
TICAROS Co., Ltd.
Monte Rosa Therapeutics, Inc
Bristol-Myers Squibb
BeOne Medicines
Tanabe Pharma Corporation
SymBio Pharmaceuticals
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Incyte Corporation
Genmab
Incyte Corporation
Ipsen
Incyte Corporation
Immunitas Therapeutics
Karyopharm Therapeutics Inc
Sichuan Baili Pharmaceutical Co., Ltd.
BeiGene
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Pfizer
Zhejiang Teruisi Pharmaceutical Inc.
Hoffmann-La Roche
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Genfleet Therapeutics (Shanghai) Inc.
Autolus Limited
Antengene Corporation
Novartis
Pell Bio-Med Technology Co., Ltd.
IDP Discovery Pharma S.L.
Gamida Cell ltd
Oncternal Therapeutics, Inc
Genmab
Shanghai Blueray Biopharma Co., Ltd.
MingSight Pharmaceuticals, Inc
Gilead Sciences
Celgene
Ipsen
Gilead Sciences